This randomized phase II study assessed the efficacy and safety of obatoclax mesylate , a small-molecule Bcl-2 inhibitor , added to carboplatin/etoposide chemotherapy as initial treatment for extensive-stage small-cell lung cancer ( ES-SCLC ) .